Analyst Price Target is $37.43
▲ +58.26% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Dyne Therapeutics in the last 3 months. The average price target is $37.43, with a high forecast of $56.00 and a low forecast of $22.00. The average price target represents a 58.26% upside from the last price of $23.65.
Current Consensus is
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Dyne Therapeutics. This Buy consensus rating has held steady for over two years.
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Read More